Sporadic Angiomyolipomas (AMLs)
Conditions
Brief summary
The purpose of this research study is to see if oral everolimus is tolerable and effective in the treatment of sporadic Angiomyolipomas (AMLs). AMLs are the most common non-cancerous tumor of the kidney. They are composed of blood vessels, muscle cells and fat cells.Everolimus is already an approved drug for several other diseases like kidney cancer, but is being studied now specifically to see if it is helpful for people with AML.
Detailed description
Primary Objective 1\. To evaluate the efficacy and tolerability of everolimus in reducing tumor volume in sporadic AMLs as measured by dynamic contrast enhanced magnetic resonance imaging (DCE MRI), in patients who might otherwise be considered for active surgical or percutaneous intervention. Secondary Objectives 1. To evaluate health-related quality of life (HRQoL) in subjects treated with everolimus for sporadic AMLs. 2. To assess the growth kinetics of sporadic AMLs in patients who have been treated with everolimus as part of the study and demonstrate an objective response as well as those who have been treated with everolimus during the study with a suboptimal or no response. 3. To measure the rate of surgical or percutaneous (embolization) intervention at 1 year from day 1 of study. 4. To assess the safety and tolerability of everolimus in patients with sporadic AML.
Interventions
DRUGEverolimus
10 mg tablets
Sponsors
Novartis Pharmaceuticals
Fox Chase Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Must have a diagnosis of renal AML \> 3 cm confirmed on pre-enrollment Dynamic Contrast Enhanced MRI (DCE-MRI) * Must not have received any prior treatment for AML * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 * Absolute neutrophil count \>= 1,500/ microliter (mcL) * Hemoglobin \>=10 g/dL * Platelets \>= 100,000/ mcL * international normalized ratio (INR) \<= 1.2 X Upper limit Normal (ULN) * activated partial thromboplastin time (aPTT) \<= 1.2 X ULN * aspartate aminotransferase (AST) / alanine transaminase (ALT) \<= 2.5 X ULN * Total bilirubin \<= 2.0mg/dL * Renal Function epidermal growth factor receptor (eGFR) \>= 30 mL/min via calculated creatinine clearance * Fasting serum cholesterol \<= 300 mg/dL OR \<= 7.75 mmol/L AND fasting triglycerides \<= 2.5x ULN.
Exclusion criteria
* History of tuberous sclerosis, LAM or any active malignancy * Treatment with any other investigational agents for any other disease * Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding or affect absorption of investigational product * Active diarrhea of any grade. * History of human immunodeficiency virus (HIV) infection, hepatitis B or C (screening for all three is mandatory prior to study); prior hepatitis C infection * Presence of any active or ongoing infection. * Any known uncontrolled underlying pulmonary disease by history, physical exam or if applicable pulmonary function test (PFTs) * History of certain cardiovascular conditions within the past 6 months * History of Class III or IV congestive heart failure, as defined by the New York Heart Association Classification of Congestive Heart Failure. * History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. * Corrected QT interval (QTc) \> 480 milliseconds * Poorly controlled hypertension, defined as systolic blood pressure (SBP) of \>= 140 millimeters of mercury(mmHg) or diastolic blood pressure (DBP) of \>= 90 mmHg. * Evidence of active bleeding or bleeding diathesis * Uncontrolled diabetes mellitus (defined by a Hgb A1c \>8) obtained within 14 days prior to registration. Optimal glucose control (Hgb A1c \<= 8) must be achieved before registration and monitored during protocol treatment * Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures. * Unable or unwilling to discontinue use of prohibited medications * Concurrent therapy given to treat cancer including treatment with an investigational agent or concurrent participation in another clinical trial involving anti-cancer investigational drug. * Administration of any investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment. * Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to everolimus * Prior or current use of systemic anti-vascular endothelial growth factor (VEGF) inhibitors, cytokines or mechanistic target of rapamycin (mTOR) inhibitors (e.g. interferon, interleukin 2). * Pregnant or nursing (lactating) women * Women of child-bearing potential (WOCBP) must use highly effective methods of contraception during the study and 8 weeks after. * Unable to obtain a contrast (gadolinium) based DCE MRI, including include patients with pacemakers, automatic implantable cardioverter/defibrillator (AICDs), non MRI compatible metallic implants or eGFR \<30. * Must not have received immunization with an attenuated live vaccine within seven days prior to registration nor have plans to receive such vaccination while on protocol treatment * Must not be taking, nor plan to take while on protocol treatment, strong cytochrome P450 3A4 (CYP3A4) inhibitors, (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, fluvoxamine, nefazodone, nelfinavir, ritonavir) and/or strong CYP3A4 inducers (e.g. phenytoin, rifampin, rifabutin) within 14 days prior to randomization. * History of another primary malignancy, with the exceptions of: non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from which the patient has been disease free for \>= 3 years * Childs-Pugh A-C liver disease (Appendix II)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With Tumor Volume Reduction Greater Than 25% | 12 months | Measuring the efficacy and tolerability of everolimus by measuring the number of patients with tumor volume reduction greater than 25% in sporadic AMLs as measured by DCE MRI |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Tolerability of Everolimus in Patients With Sporadic AML | 12 months | Number of participants with treatment-related adverse events requiring dose reduction or study withdrawal as assessed by Common Toxicity Criteria for Adverse Effects (CTCAE v4.0) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Everolimus) Patients will take 10 mg (1 tablet) of everolimus each day for 4 months
Everolimus: 10 mg tablets | 20 |
| Total | 20 |
Baseline characteristics
| Characteristic | Treatment (Everolimus) |
|---|---|
| Age, Continuous | 68 years |
| AML volume | 47.3 cc |
| BMI | 29.4 kg/m^2 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 18 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 19 Participants |
| Region of Enrollment United States | 20 participants |
| Sex: Female, Male Female | 15 Participants |
| Sex: Female, Male Male | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 20 |
| other Total, other adverse events | 20 / 20 |
| serious Total, serious adverse events | 3 / 20 |
Outcome results
Primary
Number of Patients With Tumor Volume Reduction Greater Than 25%
Measuring the efficacy and tolerability of everolimus by measuring the number of patients with tumor volume reduction greater than 25% in sporadic AMLs as measured by DCE MRI
Time frame: 12 months
Population: Some participants experienced adverse events and were withdrawn from the study, and therefore tumor volume reduction was not measured in these patients.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Everolimus) | Number of Patients With Tumor Volume Reduction Greater Than 25% | 5 Participants |
Secondary
Safety and Tolerability of Everolimus in Patients With Sporadic AML
Number of participants with treatment-related adverse events requiring dose reduction or study withdrawal as assessed by Common Toxicity Criteria for Adverse Effects (CTCAE v4.0)
Time frame: 12 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Everolimus) | Safety and Tolerability of Everolimus in Patients With Sporadic AML | 10 Participants |